The antidepressant sertraline downregulates Akt and has activity against melanoma cells

Pigment Cell and Melanoma Research

Volumn 21, Issue 4, 2008, Pages 451-456

  Reddy, Kalpana K ^a   Lefkove, Benjamin ^a   Chen, Lan Bo ^b   Govindarajan, Baskaran ^a   Carracedo, Arkaitz ^c   Velasco, Guillermo ^c   Carrillo, Carol O ^a   Bhandarkar, Sulochana S ^a   Owens, Michael J ^a   Mechta Grigoriou, Fatima ^d   Arbiser, Jack L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d INSTITUT PASTEUR   (France)

Author keywords

AKT; Melanoma; Reactive oxygen; Sertraline; Signal transduction; SSRI

Indexed keywords

CASPASE 9; HYDROGEN PEROXIDE; PROTEIN KINASE B; S6 KINASE; SERTRALINE; SUPEROXIDE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; MALE; MELANOMA; MICE; MICE, NUDE; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; SERTRALINE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 47249133437     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2008.00481.x     Document Type: Article

References (33)

1. Arbiser, J.L., Moses, M.A., Fernandez, C.A. et al. (1997). Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl Acad. Sci. U. S. A 94, 861 866.
2. Arbiser, J.L., Bingaman, A., Durham, M., Cowan, S., Cohen, C., Zarnegar, E., Varma, V. Larsen, C.P. (2002a). SVR angiosarcomas can be rejected by CD4 costimulation dependent and CD8 costimulation independent pathways. Mol. Med. 8, 551 558.
3. Arbiser, J.L., Petros, J., Klafter, R. et al. (2002b). Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc. Natl Acad. Sci. U. S. A 99, 715 720.
4. Barbey, J.T. Roose, S.P. (1998). SSRI safety in overdose. J. Clin. Psychiatry 59 (Suppl. 15 42 48.
5. Campioni, M., Santini, D., Tonini, G., Murace, R., Dragonetti, E., Spugnini, E.P. Baldi, A. (2005). Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp. Dermatol. 14, 811 818.
6. Cohen, C., Zavala-Pompa, A., Sequeira, J.H., Shoji, M., Sexton, D.G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N. Arbiser, J.L. (2002). Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 8, 3728 3733.
7. Dai, D.L., Martinka, M. Li, G. (2005). Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 23, 1473 1482.
8. Danson, S. Lorigan, P. (2005). Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs 65, 733 743.
9. Ernst, D.S., Eisenhauer, E., Wainman, N., Davis, M., Lohmann, R., Baetz, T., Belanger, K. Smylie, M. (2005). Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest. New Drugs 23, 569 575.
10. Fernandez, Y., Verhaegen, M., Miller, T.P., Rush, J.L., Steiner, P., Opipari, A.W., Jr., Lowe, S.W. Soengas, M.S. (2005). Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res. 65, 6294 6304.
11. Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117 122.
12. Goeringer, K.E., Raymon, L., Christian, G.D. Logan, B.K. (2000). Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J. Forensic Sci. 45, 633 648.
13. Govindarajan, B., Klafter, R., Miller, M.S., Mansur, C., Mizesko, M., Bai, X., LaMontagne, K. Jr. Arbiser, J.L. (2002). Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol. Med. 8, 1 8.
14. Govindarajan, B., Shah, A., Cohen, C. et al. (2005). Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB. J. Biol. Chem. 280, 13936 13943.
15. Govindarajan, B., Sligh, J.E., Vincent, B.J. et al. (2007). Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J. Clin. Invest. 117 719 729.
16. Gupta, P.B., Kuperwasser, C., Brunet, J.P., Ramaswamy, S., Kuo, W.L., Gray, J.W., Naber, S.P. Weinberg, R.A. (2005). The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 37, 1047 1054.
17. Karakousis, C.P., Getaz, E.P., Bjornsson, S. et al. (1979). cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma. Cancer Treat. Rep. 63, 2009 2010.
18. Maker, A.V., Yang, J.C., Sherry, R.M. et al. (2006). Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 29, 455 463.
19. Mansour, S.J., Matten, W.T., Hermann, A.S., Candia, J.M., Rong, S., Fukasawa, K., Vande Woude, G.F. Ahn, N.G. (1994). Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966 970.
20. McConathy, J., Capello, C., Jarkas, N., Stowe, Z.N. Owens, M.J. (2007). Preparation of antidepressants for use in preclinical research. International J Neuropsychopharmacology 10, 759 763.
21. Meyskens, F.L. Jr., McNulty, S.E., Buckmeier, J.A., Tohidian, N.B., Spillane, T.J., Kahlon, R.S. Gonzalez, R.I. (2001). Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic. Biol. Med. 31, 799 808.
22. Musselman, D.L., Lawson, D.H., Gumnick, J.F., Manatunga, A.K., Penna, S., Goodkin, R.S., Greiner, K., Nemeroff, C.B. Miller, A.H. (2001). Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344, 961 966.
23. Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B.A. Yuan, J. (2000). Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403, 98 103.
24. Owens, M.J., Morgan, W.N., Plott, S.J. Nemeroff, C.B. (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283, 1305 1322.
25. Owens, M.J., Knight, D.L. Nemeroff, C.B. (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 50, 345 350.
26. Pahl, H.L. Baeuerle, P.A. (1996). Activation of NF-kappa B by ER stress requires both Ca2+ and reactive oxygen intermediates as messengers. FEBS Lett. 392, 129 136.
27. Panka, D.J., Wang, W., Atkins, M.B. Mier, J.W. (2006). The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 66, 1611 1619.
28. Pollock, P.M. Meltzer, P.S. (2002). A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2, 5 7.
29. Robertson, G.P. (2005a). Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 24, 273 285.
30. Sander, C.S., Chang, H., Hamm, F., Elsner, P. Thiele, J.J. (2004). Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int. J. Dermatol. 43, 326 335.
31. Shattuck-Brandt, R.L. Richmond, A. (1997). Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res. 57, 3032 3039.
32. Sung, S.Y., Kubo, H., Shigemura, K. et al. (2006). Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res. 66, 9519 9526.
33. Tuveson, D.A., Weber, B.L. Herlyn, M. (2003). BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4, 95 98.